

22nd February, 2008



**Eastland Medical
Systems LTD**

ACN 090 987 250

The Manager,
The Company Announcements Platform,
Australian Securities Exchange Limited,
Level 4, 20 Bridge Street,
Sydney. N.S.W. 2000.

E-lodgement ASX Online 15 pages

**MEDIA RELAESE.
POWER POINT PRESENTATION**

Eastland Medical Systems Ltd (Eastland®) wish to provide and update for the Company's Power Point Presentation last issued on 9th July 2007.

This presentation is also available for download from the Company's website at www.eastlandmedical.com.au

Yours sincerely,

T.P. Strahan.
Company Secretary.

54 Lindsay Street
Perth 6000
Western Australia

PO Box 8027
Perth BC 6849
Western Australia

(T) 61 8 9436 9500
(F) 61 8 9436 9505

(E) eastland@eastlandmedical.com.au
(W) www.eastlandmedical.com.au



Eastland Medical Systems Ltd

www.eastlandmedical.com.au

February 2008



Capital Structure

Share Price (\$) A\$0.17

Fully paid ordinary Shares (m) 176

Unlisted Options (20c, May 2011) (m) 29

Unlisted Options (20c, August 2008) (k) 340

Unlisted Options (15c, August 2008) (k) 500

Market cap fully diluted (m) 35

Share Price Year High-Low (\$) A\$0.265-A\$0.10

Top 20 (%)

FEE-ZONE PTY LTD	10.22
O'SULLIVAN SUPERANNUATION FUND	7.86
ANZ NOMINEES LIMITED	7.80
RBC DEXIA INVESTOR SERVICES	4.49
EASTLAND TECHNOLOGY AUSTRALIA LTD	4.35
HSBC CUSTODY NOMINEES LTD	3.57
ONICAS INVESTMENTS PTY LTD	2.31
GRANWORLD PTY LTD	1.80
PALOS PTY LTD	1.71
DOUGALL RETIREMENT FUND	1.63
FIRST MANHATTAN SECURITIES PTY LTD	1.02
BOTSIS HOLDINGS PTY LTD	0.85
MR JOHN FIRTH	0.85
MR CALVIN JOHN ROSS	0.57
MR BEN FAN	0.44
SYNTHE PTY LTD	0.42
MR GRANT TANNER	0.42
NEST EGG SUPERANNUATION FUND	0.40
KINGSLEY PLACE PTY LTD	0.37
DOUGLAS SIMS	0.36



ArTiMist™: New Anti-Malaria Treatment

- **Proven formula with a more effective method of administration through improved absorption**
- **Attacks malaria parasite at far greater speed than the conventional tablets**
- **Removes the need for advanced clinical intervention**
- **Reduces need for continued hospitalisation = cost savings to Governments and relief organisations**
- **Price Competitive**

The results of a single dose human clinical trial of ArTiMist™ recently completed in Penang indicate that the new delivery method and formulation is well tolerated and showed no adverse reactions.



Malaria

ArTiMist™: New Anti-Malaria Treatment

“ArTiMist™ is a treatment for malaria in young infants and children which uses a multiple dose spray device for delivery under the tongue – ‘Sublingual’ – of a drug known as Artemether.

This drug is currently available in a tablet and injection form. However, tablet administration in young children is difficult – particularly due to vomiting and high fever conditions – and injections require trained personnel and are hard to administer in very sick children.

The Sublingual Mouth Spray (ArTiMist™) overcomes all of these obstacles and is very easy to use even in the most remote areas and difficult circumstances.”


Calvin J Ross

Director of Development

ProtoPharma Ltd UK




Malaria Infected Regions





Worldwide Malaria Cases

Reported 500 million cases worldwide



Source: World Health Organisation



The Market for Malaria

Global Market – The Malaria Crisis

- A child dies of malaria every 30 seconds
- 500 million cases of malaria worldwide PA
- 41% of global population at risk
- Accounts for 40% of public health expenditure in Africa
- **Global Fund (GFATM)** - financial pledges worth up to US\$9.7billion over three years secured to fight AIDS, Tuberculosis and Malaria.
- **WHO** report that up to US\$2 billion will be needed each year to achieving the goal of halving the burden of malaria by 2010.

Global warming = malaria on the increase

Sources: World Health Organisation & Global Fund to Fight AIDS, Tuberculosis and Malaria,




Malaria

ArTiMist™ Forecast Revenues

	Year 1 2008	Year 2 2009	Year 3 2010	Year 4 2011
Africa	\$4.0M	\$22.0M	\$33.0M	\$37.0M
Asia	\$8.0M	\$19.0M	\$28.0M	\$48.0M



Malaria Project Timeline






Commercial Relationships

NiCoSorb™ Owner of IP & royalty US\$0.20 p/unit globally
Exclusive Distribution Australasia, Asia, Japan & China

ArTiMist™ Owner of IP & Exclusive
Distribution India, Asia & Pacific Islands

Owner of IP ClipOn®, Vetlok®,
Exclusive Manufacturer
& Distributor USA, Asia & Pacific Islands



ArTiMist™ Exclusive Distribution
Sub-Sahara Africa

ClipOn®-Vetlok® Exclusive
Distribution for African Continent

ArTiMist™ Exclusive
Distribution North Africa

Owner of ArTiMist™ IP
for African Continent

Exclusive Manufacturer ArTiMist™
Africa, Asia, India & Pacific Islands

Manufacturer NiCoSorb™ & Distributor
Europe

ClipOn®-Vetlok® Exclusive Distributor
Germany

World IP Tamper Evident & Child Proof
Packaging.

Manufacturer & Distributor Medisheet®
Europe



February 2008

Overview

Solid Revenue Base

- Organic growth + Growth through acquisitions = Increasing Revenues

Malaria Project – Global Market

- Ownership of IP
- Forecast Yr1 (2008) \$12m increasing to \$85m in Yr 4 (2011) of production
- Exclusive Manufacture & Distribution anti-malaria treatment **ArTiMist™** –
Africa Asia, India, & Pacific Islands
- Regulatory approvals completed in Asia & expect completion of South Africa study end Feb 2008
- Sales expected Q1- Q2 08 and increased manufacturing Q2 08

ClipOn® Safe Needle Device

- CE Marked, distributors for Vetlok® (veterinary version) & ClipOn® (health)
- To be marketed in conjunction with **ArTiMist™**



February 2008

New Project

New Anti – Smoking Replacement Therapy

- **Ownership of IP**
- **Exclusive Distribution Rights – Asia, India, Australia, Pacific Island & China**
- **Removes cravings for up to 9 hours – Improved Lifestyle (growing restrictions)**
- **Royalties of US\$0.20 for each unit of NiCoSorb™ produced globally.**



Directors

Peter Jooste QC

Chairman, Non-Executive Director

Peter brings to Eastland his widespread knowledge in all areas of Corporate Law

Douglas Sims

Executive Director

Doug has considerable experience in the development of products from concept to commercial production

Dermot Patterson

CEO, Executive Director

Dermot has had along career in the global healthcare market which has provided a wealth of international marketing experience

Peter Tiede

CFO, Executive Director

Peter brings 10 years of extensive experience of the field of Corporate finance to the Group

David Whitelaw

Non-Executive Director

David brings to Eastland a broad business background and expertise in healthcare and biotechnology industries.



Disclaimer & Confidentiality Notice

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation whether orally or in writing by or on behalf of Eastland Medical Systems Ltd ("Eastland®") or their respective employees, agents or consultants ("Information") is provided to the Recipients on the terms and conditions set out in this notice.

The Presentation contains reference to certain intentions, expectations and plans of Eastland®. Those intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ. The performance and operations of Eastland® may be influenced by a number of factors, many of which are outside the control of Eastland®. No representation or warranty, express or implied, is made by Eastland® or any of its respective directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

The Presentation does not purport to contain all the information that any existing or prospective investor may require. It is not intended to be a complete or accurate statement of material information. In all cases, before acting in reliance on any information, the Recipient should conduct its own investigation and analysis in relation to the business opportunity and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

The Recipient should not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and should consult its own advisers. Eastland® and its advisers take no responsibility for the contents of the Presentation.

Eastland® makes no representation or warranty (express or implied) as to the accuracy, reliability or completeness of the information. Eastland® and its respective directors, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Presentation, except liability under statute that cannot be excluded.